Health Technology Assessment is a key tool for appraising available evidence to inform health care policy. The global shift towards value rather than cost has encouraged the introduction of HTA processes in developing markets in order to ensure relevant, timely and economically efficient decision making. European and international agencies such as EUnetHTA and HTAi have encouraged cross country and market learnings and I think we will see the rapid introduction of HTA to inform evidence based decision making in many more countries over the coming years. Industry must prepare in advance for established and developed HTA body submissions, ensuring gaps are filled and value demonstrated to enable timely market and patient access.
Ruth is a Practice Lead for DRG Abacus and has domain expertise in Health Technology Assessment (HTA).
Ruth has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes and excellent relationships with the main HTA bodies. Ruth works closely with clients and in-house teams, advising manufacturers on their role and requirements, and significantly contributes to the development and communication of HTA strategy.
Ruth joined Abacus from the National Institute for Health and Care Excellence (NICE) in 2009 and has over 12 years’ experience in health outcomes research.
Ruth holds an MSc in Health Economics from the University of York and her experience in health outcomes research covers a wide range of therapeutic areas.